Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
By Patrick Wingrove (Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead...
Read moreBy Patrick Wingrove (Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead...
Read moreInvesting.com — Analysts at Citi revised their transportation stock ratings on Tuesday, citing valuation concerns that emerged following a post-election...
Read moreInvesting.com — Phillip Capital downgraded Airbnb to Reduce from Neutral on Tuesday, citing high valuations and limited near-term upside due to...
Read moreInvesting.com — Shares of Drax Group (LON:DRX) jumped over 6% on Tuesday following an announcement indicating the company’s expected EBITDA...
Read moreInvesting.com – Accelerated computing power and demand from enterprise, government and cloud service providers are both due to drive growth at...
Read moreInvesting.com — The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza...
Read moreInvesting.com – AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its...
Read moreBy Zaheer Kachwala (Reuters) -Tesla shares jumped more than 6% premarket on Monday (NASDAQ:MNDY), extending a rally fueled by investor...
Read moreOn Monday (NASDAQ:MNDY), MicroStrategy Incorporated (NASDAQ:MSTR), known for holding the largest corporate Bitcoin treasury, announced the acquisition of approximately 27,200...
Read moreOppenheimer AM lifted its 2024 year-end price target for the S&P 500 from 5,900 to 6,200. This marks the third...
Read moreCopyright © 2025 Insightfulword.com. All Rights Reserved.